C-TCR055, AFP specific TCR T cell injection, was selected for function and safety from TCR profiles, and has been used to initiate phase I clinical trials for unresectable HCC therapy (NCT03971747, NCT04368182) [73]. Here, AFP is linked to hepatocellular carcinoma.